Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

REGENXBIO

Tracked across 3 events · 134 articles · First seen Apr 01, 2026 · Last active Aug 20, 2026

Sentiment
-22
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -70
Business
Impact: REGENXBIO is the defendant in a class action lawsuit alleging that it made false and misleading statements regarding its gene therapy product candidate RGX-111, leading to investor losses. The lawsuit claims REGENXBIO concealed negative efficacy and safety data, including the discovery of a CNS tumor in a study participant.
Apr 01, 2026 · 26 articles
6 0
Regulatory
Impact: REGENXBIO has an exclusive worldwide license with Novartis for recombinant AAV vectors used in SMA gene replacement therapy, indirectly benefiting from Itvisma's approval.
Jul 02, 2026 · 7 articles
6 5
Domestic
President Donald Trump nominated Dr. Heidi Overton, a White House domestic policy aide, to lead the U.S. United States — Food and Drug Administration (FDA). Overton, a physician and deputy director of the White House…
Impact: REGENXBIO benefited from the FDA's reversal under Diamantas. Overton's policies could affect rare-disease therapies.
Aug 19, 2026 · 101 articles
ERGEN INTELLIGENCE
Track REGENXBIO live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.